Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?

Documenti analoghi

• Increased risk of hypereosinophilia following initiation of glucagon‐like peptide 1 receptor agonist: A symmetry analysis using the Danish health registries
  di: Martin Torp Rahbek, et al.
  Pubblicazione: (2024)
• Depression following the initiation of glucagon‐like‐peptide‐1 receptor agonist therapy: A multinational self‐controlled case series study
  di: Vincent Ka Chun Yan, et al.
  Pubblicazione: (2026)
• Fatigue and mood disorders are highly prevalent in patients with inflammatory bowel disease: A single‐centre, cross‐sectional study using patient‐reported outcomes
  di: Andrew Chen, et al.
  Pubblicazione: (2026)
• Clinical implications of using different methods for estimating kidney function in older hospitalised patients: creatinine, cystatin C, or both
  di: Ramya D Rajkumar, et al.
  Pubblicazione: (2025)
• Are Australians living with dementia ready for new therapies?
  di: Sean Maher, et al.
  Pubblicazione: (2025)